Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment
MWN-AI** Summary
Avant Technologies, Inc. has identified cell encapsulation technology as a critical component in revolutionizing diabetes treatment. The biotechnology firm, specializing in cell-based therapies for diabetes and age-related diseases, has partnered with SGAustria Pte. Ltd., a leader in cell encapsulation, to form a joint venture named Insulinova, Inc. This collaboration aims to advance diabetes care by developing genetically modified cells that can produce, store, and secrete insulin—mimicking the function of healthy pancreatic beta cells.
With diabetes affecting 1 in 9 adults globally and the number of affected individuals expected to rise significantly, advancements in treatment are crucial. Current management practices, such as insulin injections and pumps, merely alleviate symptoms without addressing the underlying problem. Avant's approach, powered by SGAustria's proprietary Cell-in-a-Box® technology, offers a potential solution by encapsulating insulin-producing cells. This encapsulation not only protects these cells from immune rejection but also enables them to function effectively within the body without the need for long-term immunosuppressive drugs.
Recent studies have shown promising results with encapsulated stem cell-derived beta cells demonstrating effective glucose control, thus enhancing the overall well-being of patients. The partnership between Avant and SGAustria is positioned at the forefront of innovation within this field, potentially eliminating the burdens of daily insulin management. Avant CEO Chris Winter emphasized that this technology minimizes immune rejection and mitigates risks of complications such as tumor formation, making it a cornerstone for scalable and safe diabetes therapies.
Avant Technologies continues to be at the vanguard of biotechnology, enhancing the quality of life for millions living with diabetes, while laying down frameworks for a future free from daily intervention.
MWN-AI** Analysis
Avant Technologies, Inc. (OTCQB: AVAI) is positioning itself as a key player in the biotechnology sector, leveraging breakthrough cell encapsulation technology to fundamentally change diabetes treatment. With over 1 in 9 adults affected by diabetes globally, the need for effective solutions is critical. The company’s collaboration with SGAustria Pte. Ltd. to develop Insulinova, Inc. showcases a promising approach that could address long-standing challenges in diabetes management.
Cell encapsulation, particularly through the patented Cell-in-a-Box® technology, provides a vital advancement by allowing genetically modified insulin-producing cells to function in the body without the risk of immune rejection. This innovative encapsulation creates a protective barrier around the cells, enabling them to secrete insulin in response to glucose levels while avoiding the need for immunosuppressive drugs. As the market is projected to see an increase in diabetes cases—up to 853 million by 2050—Avant's technology could soon cater to a vast and growing patient population.
For investors, Avant Technologies offers a compelling opportunity. The company's focus on cutting-edge biotechnology and its strategic alliances bode well for future growth. As they continue to progress through clinical trials and potentially move towards market commercialization, investors should monitor key developments closely, including trial outcomes and regulatory approvals.
Moreover, as an emerging leader in regenerative medicine, Avant stands to benefit from increased interest in biotech investments, particularly in the context of chronic disease management. Given the increasing incidence of diabetes and the shortcomings of current treatment options, Avant’s innovative therapies could fulfill a substantial market need. Investors should consider adding AVAI to their portfolios, keeping in mind the inherent risks associated with biotechnology stocks, including regulatory hurdles and market acceptance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
LAS VEGAS, Dec. 16, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today highlights the essential importance of cell encapsulation technology in enabling effective, long-term treatments for type 1 and insulin-dependent type 2 diabetes. By protecting genetically modified cells that produce and secrete insulin, this innovative approach addresses key barriers to cell-based therapies, offering hope for millions of patients worldwide who rely on daily insulin injections.
Last month Avant and SGAustria Pte. Ltd. (SGAustria), a leading biotechnology company specializing in clinically proven cell encapsulation, formed a groundbreaking joint venture and license agreement aimed at revolutionizing a diabetes treatment through innovative stem cells and/or other cells combined with encapsulation technologies. The partnership will lead to the creation of Insulinova, Inc., a U.S. company, to facilitate and conduct clinical trials.
According to the International Diabetes Federation (IDF), 1 in 9 adults (20-79 years) is living with diabetes, while another 4 in 10 are unaware that they have the condition. The IDF estimates that 589 million people globally live with both type 1 and insulin-dependent type 2 requiring constant management to prevent life-threatening complications. And the IDF is projecting that by 2050, approximately 853 million people will be living with diabetes—a 46% increase.
Traditional treatments, such as insulin pumps or injections, provide symptom relief but do not cure the underlying issue: the body's inability to produce sufficient insulin. Avant and SGAustria's diabetes development program focuses on genetically modified cells engineered to produce, store, and secrete insulin in response to blood glucose levels, mimicking the function of healthy pancreatic beta cells.
However, historically, a major challenge in deploying these cells has been the immune system's rejection of implanted foreign material, often necessitating lifelong immunosuppressive drugs that carry significant risks. Cell encapsulation technology—like SGAustria's Cell-in-a-Box®—overcomes this challenge by creating a protective barrier around the cells, shielding them from immune attacks while allowing nutrients, oxygen, and insulin to pass through freely. This encapsulation enables the safe, sustained delivery of insulin without the need for immunosuppression, potentially providing a functional cure for type 1 diabetes and reducing dependency on external insulin for affected type 2 patients.
Brian Salmons, Chief Executive Officer (CEO) at SGAustria, said, "Our Cell-in-a-Box® technology is a pivotal advancement for a diabetes treatment, and through our joint venture with Avant, we are poised to deliver a transformative therapy. By safeguarding insulin-producing cells from immune rejection while ensuring long-term functionality, we're paving the way for a future where patients can manage diabetes without the burden of daily interventions."
Recent advancements in encapsulation devices, including Cell-in-a-Box® have demonstrated promising results in preclinical and clinical studies. For instance, encapsulated stem cell-derived beta cells have been shown to exert glucose control in patients, resolving hypoglycemic events and enhancing overall well-being. Avant and SGAustria's ongoing research builds on these breakthroughs, with secured joint venture and licensing agreements to integrate state-of-the-art encapsulation with its planned cell-based diabetes treatment. This positions the company at the forefront of developing therapies that could eliminate the burden of daily insulin management.
"Cell encapsulation is a game-changer in the field of regenerative medicine," added Chris Winter, CEO at Avant. "By partnering with SGAustria, we're ensuring that any genetically modified insulin-producing cells that we develop together can thrive in the body long-term and offer the potential of restoring natural glucose control and dramatically improving patients' quality of life. This technology not only minimizes risks like immune rejection but also prevents potential complications such as cell escape or tumor formation, making it a cornerstone for safe and scalable diabetes therapies."
About Avant Technologies, Inc.Avant Technologies, Inc. is an emerging biotechnology company focused on identifying genetically modified cells lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
About SGAustria Pte. Ltd.SGAustria, based in Singapore, is a leading biotechnology company specializing in clinically proven cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global biotech companies.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI https://www.facebook.com/AvantTechAI https://www.youtube.com/@AvantTechAI
Forward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc. info@avanttechnologies.com
Logo - https://mma.prnewswire.com/media/2840805/5683395/Avant_Technologies_Logo.jpg
SOURCE Avant Technologies Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2025/16/c7808.html
FAQ**
How does Avant Technologies Inc. (OTCQB: AVAI) plan to leverage its joint venture with SGAustria to advance its cell encapsulation technology for diabetes treatment?
What specific regulatory hurdles must Avant Technologies Inc. (AVAI) overcome to conduct clinical trials for its encapsulated cell therapies in diabetes management?
In what ways does Avant Technologies Inc. (AVAI) expect its Cell-in-a-Box® technology to differentiate itself from traditional diabetes treatments in terms of efficacy and patient quality of life?
As the global diabetes population is projected to reach 853 million by 2050, how is Avant Technologies Inc. (AVAI) positioning itself to meet the rising demand for innovative diabetes therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Avant Technologies Inc. (OTC: AVAI).
NASDAQ: AVAI
AVAI Trading
-2.72% G/L:
$0.358 Last:
63,580 Volume:
$0.3644 Open:
